Mitomycin C: a promising agent for the treatment of canine corneal scarring
Objective To evaluate the safety and efficacy of mitomycin C (MMC) in prevention of canine corneal scarring. Methods With an in vitro approach using healthy canine corneas, cultures of primary canine corneal fibroblasts or myofibroblasts were generated. Primary canine corneal fibroblasts were obta...
Gespeichert in:
| Veröffentlicht in: | Veterinary ophthalmology 2011-09, Vol.14 (5), p.304-312 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 312 |
|---|---|
| container_issue | 5 |
| container_start_page | 304 |
| container_title | Veterinary ophthalmology |
| container_volume | 14 |
| creator | Gupta, Rangan Yarnall, Benjamin W. Giuliano, Elizabeth A. Kanwar, Jagat R. Buss, Dylan G. Mohan, Rajiv R. |
| description | Objective To evaluate the safety and efficacy of mitomycin C (MMC) in prevention of canine corneal scarring.
Methods With an in vitro approach using healthy canine corneas, cultures of primary canine corneal fibroblasts or myofibroblasts were generated. Primary canine corneal fibroblasts were obtained by growing corneal buttons in minimal essential medium supplemented with 10% fetal bovine serum. Canine corneal myofibroblasts were produced by growing cultures in serum‐free medium containing transforming growth factor β1 (1 ng/mL). Trypan blue assay and phase‐contrast microscopy were used to evaluate the toxicity of three doses of MMC (0.002%, 0.02% and 0.04%). Real‐time PCR, immunoblot, and immunocytochemistry techniques were used to determine MMC efficacy to inhibit markers of canine corneal scarring.
Results A single 2‐min treatment of 0.02% or less MMC did not alter canine corneal fibroblast or keratocyte phenotype, viability, or growth. The 0.02% dose substantially reduced myofibroblast formation (up to 67%; P |
| doi_str_mv | 10.1111/j.1463-5224.2011.00877.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3354612</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1420128491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6097-45afdc1f4cf64593b4f57722438a0a3070a7c5678d9dccbf796de08f328b936f3</originalsourceid><addsrcrecordid>eNqNUU1v1DAUtBCIlsJfQD5ySbDjrwQhJLSiW0RLkfg6Pnkde-slibd2lu7-exy2RHDDFz_5zcwbz0MIU1LSfF5uSsolK0RV8bIilJaE1EqV-wfodG48nGsqT9CTlDaEECaIeoxOKtpUjSTqFH248mPoD8YPePEKa7yNoffJD2us13YYsQsRjzcWj9HqsZ9egsNGD36w2IQ4WN3hZHSMmfIUPXK6S_bZ_X2Gvp6_-7K4KC6vl-8Xby8LI0mjCi60aw113DjJRcNW3AmlsmNWa6IZUUQrI6Sq26Y1ZuVUI1tLaseqetUw6dgZenPU3e5WvW1NdhV1B9voex0PELSHfzuDv4F1-AmMCS5plQVe3AvEcLuzaYT8Z2O7Tg827BJQnkOtat7QDK2PUBNDStG6eQwlMO0CNjDFDFPkMO0Cfu8C9pn6_G-bM_FP-Bnw-gi48509_LcwfLv-lItML450n0a7n-k6_gCpmBLw_eMSllf1eSPkZ1DsFxp9p3I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1420128491</pqid></control><display><type>article</type><title>Mitomycin C: a promising agent for the treatment of canine corneal scarring</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Gupta, Rangan ; Yarnall, Benjamin W. ; Giuliano, Elizabeth A. ; Kanwar, Jagat R. ; Buss, Dylan G. ; Mohan, Rajiv R.</creator><creatorcontrib>Gupta, Rangan ; Yarnall, Benjamin W. ; Giuliano, Elizabeth A. ; Kanwar, Jagat R. ; Buss, Dylan G. ; Mohan, Rajiv R.</creatorcontrib><description>Objective To evaluate the safety and efficacy of mitomycin C (MMC) in prevention of canine corneal scarring.
Methods With an in vitro approach using healthy canine corneas, cultures of primary canine corneal fibroblasts or myofibroblasts were generated. Primary canine corneal fibroblasts were obtained by growing corneal buttons in minimal essential medium supplemented with 10% fetal bovine serum. Canine corneal myofibroblasts were produced by growing cultures in serum‐free medium containing transforming growth factor β1 (1 ng/mL). Trypan blue assay and phase‐contrast microscopy were used to evaluate the toxicity of three doses of MMC (0.002%, 0.02% and 0.04%). Real‐time PCR, immunoblot, and immunocytochemistry techniques were used to determine MMC efficacy to inhibit markers of canine corneal scarring.
Results A single 2‐min treatment of 0.02% or less MMC did not alter canine corneal fibroblast or keratocyte phenotype, viability, or growth. The 0.02% dose substantially reduced myofibroblast formation (up to 67%; P < 0.001), as measured by the change in RNA and protein expression of fibrosis biomarkers (α‐smooth muscle actin and F‐actin).
Conclusion This in vitro study suggests that a single 2‐min 0.02% MMC treatment to the canine corneal keratocytes is safe and may be useful in decreasing canine corneal fibrous metaplasia. In vivo studies are warranted.</description><identifier>ISSN: 1463-5216</identifier><identifier>EISSN: 1463-5224</identifier><identifier>DOI: 10.1111/j.1463-5224.2011.00877.x</identifier><identifier>PMID: 21929607</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>actin ; Actins ; Animals ; Apoptosis ; biomarkers ; canine ; Cicatrix ; Cicatrix - prevention & control ; cornea ; Corneal Diseases ; Corneal Diseases - drug therapy ; Corneal Keratocytes ; Corneal Keratocytes - drug effects ; culture media ; Dog Diseases ; Dog Diseases - drug therapy ; Dogs ; Dose-Response Relationship, Drug ; drug effects ; drug therapy ; fetal bovine serum ; fibroblasts ; Fibroblasts - drug effects ; fibrosis ; in vitro studies ; in vivo studies ; metaplasia ; microscopy ; mitomycin ; Mitomycin - therapeutic use ; mitomycin C ; muscles ; phenotype ; polymerase chain reaction ; prevention & control ; protein synthesis ; RNA ; Stromal Cells ; Stromal Cells - drug effects ; therapeutic use ; toxicity ; transforming growth factors ; viability</subject><ispartof>Veterinary ophthalmology, 2011-09, Vol.14 (5), p.304-312</ispartof><rights>2011 American College of Veterinary Ophthalmologists</rights><rights>2011 American College of Veterinary Ophthalmologists.</rights><rights>2011 American College of Veterinary Ophthalmologists 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6097-45afdc1f4cf64593b4f57722438a0a3070a7c5678d9dccbf796de08f328b936f3</citedby><cites>FETCH-LOGICAL-c6097-45afdc1f4cf64593b4f57722438a0a3070a7c5678d9dccbf796de08f328b936f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1463-5224.2011.00877.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1463-5224.2011.00877.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21929607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gupta, Rangan</creatorcontrib><creatorcontrib>Yarnall, Benjamin W.</creatorcontrib><creatorcontrib>Giuliano, Elizabeth A.</creatorcontrib><creatorcontrib>Kanwar, Jagat R.</creatorcontrib><creatorcontrib>Buss, Dylan G.</creatorcontrib><creatorcontrib>Mohan, Rajiv R.</creatorcontrib><title>Mitomycin C: a promising agent for the treatment of canine corneal scarring</title><title>Veterinary ophthalmology</title><addtitle>Vet Ophthalmol</addtitle><description>Objective To evaluate the safety and efficacy of mitomycin C (MMC) in prevention of canine corneal scarring.
Methods With an in vitro approach using healthy canine corneas, cultures of primary canine corneal fibroblasts or myofibroblasts were generated. Primary canine corneal fibroblasts were obtained by growing corneal buttons in minimal essential medium supplemented with 10% fetal bovine serum. Canine corneal myofibroblasts were produced by growing cultures in serum‐free medium containing transforming growth factor β1 (1 ng/mL). Trypan blue assay and phase‐contrast microscopy were used to evaluate the toxicity of three doses of MMC (0.002%, 0.02% and 0.04%). Real‐time PCR, immunoblot, and immunocytochemistry techniques were used to determine MMC efficacy to inhibit markers of canine corneal scarring.
Results A single 2‐min treatment of 0.02% or less MMC did not alter canine corneal fibroblast or keratocyte phenotype, viability, or growth. The 0.02% dose substantially reduced myofibroblast formation (up to 67%; P < 0.001), as measured by the change in RNA and protein expression of fibrosis biomarkers (α‐smooth muscle actin and F‐actin).
Conclusion This in vitro study suggests that a single 2‐min 0.02% MMC treatment to the canine corneal keratocytes is safe and may be useful in decreasing canine corneal fibrous metaplasia. In vivo studies are warranted.</description><subject>actin</subject><subject>Actins</subject><subject>Animals</subject><subject>Apoptosis</subject><subject>biomarkers</subject><subject>canine</subject><subject>Cicatrix</subject><subject>Cicatrix - prevention & control</subject><subject>cornea</subject><subject>Corneal Diseases</subject><subject>Corneal Diseases - drug therapy</subject><subject>Corneal Keratocytes</subject><subject>Corneal Keratocytes - drug effects</subject><subject>culture media</subject><subject>Dog Diseases</subject><subject>Dog Diseases - drug therapy</subject><subject>Dogs</subject><subject>Dose-Response Relationship, Drug</subject><subject>drug effects</subject><subject>drug therapy</subject><subject>fetal bovine serum</subject><subject>fibroblasts</subject><subject>Fibroblasts - drug effects</subject><subject>fibrosis</subject><subject>in vitro studies</subject><subject>in vivo studies</subject><subject>metaplasia</subject><subject>microscopy</subject><subject>mitomycin</subject><subject>Mitomycin - therapeutic use</subject><subject>mitomycin C</subject><subject>muscles</subject><subject>phenotype</subject><subject>polymerase chain reaction</subject><subject>prevention & control</subject><subject>protein synthesis</subject><subject>RNA</subject><subject>Stromal Cells</subject><subject>Stromal Cells - drug effects</subject><subject>therapeutic use</subject><subject>toxicity</subject><subject>transforming growth factors</subject><subject>viability</subject><issn>1463-5216</issn><issn>1463-5224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUU1v1DAUtBCIlsJfQD5ySbDjrwQhJLSiW0RLkfg6Pnkde-slibd2lu7-exy2RHDDFz_5zcwbz0MIU1LSfF5uSsolK0RV8bIilJaE1EqV-wfodG48nGsqT9CTlDaEECaIeoxOKtpUjSTqFH248mPoD8YPePEKa7yNoffJD2us13YYsQsRjzcWj9HqsZ9egsNGD36w2IQ4WN3hZHSMmfIUPXK6S_bZ_X2Gvp6_-7K4KC6vl-8Xby8LI0mjCi60aw113DjJRcNW3AmlsmNWa6IZUUQrI6Sq26Y1ZuVUI1tLaseqetUw6dgZenPU3e5WvW1NdhV1B9voex0PELSHfzuDv4F1-AmMCS5plQVe3AvEcLuzaYT8Z2O7Tg827BJQnkOtat7QDK2PUBNDStG6eQwlMO0CNjDFDFPkMO0Cfu8C9pn6_G-bM_FP-Bnw-gi48509_LcwfLv-lItML450n0a7n-k6_gCpmBLw_eMSllf1eSPkZ1DsFxp9p3I</recordid><startdate>201109</startdate><enddate>201109</enddate><creator>Gupta, Rangan</creator><creator>Yarnall, Benjamin W.</creator><creator>Giuliano, Elizabeth A.</creator><creator>Kanwar, Jagat R.</creator><creator>Buss, Dylan G.</creator><creator>Mohan, Rajiv R.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>201109</creationdate><title>Mitomycin C: a promising agent for the treatment of canine corneal scarring</title><author>Gupta, Rangan ; Yarnall, Benjamin W. ; Giuliano, Elizabeth A. ; Kanwar, Jagat R. ; Buss, Dylan G. ; Mohan, Rajiv R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6097-45afdc1f4cf64593b4f57722438a0a3070a7c5678d9dccbf796de08f328b936f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>actin</topic><topic>Actins</topic><topic>Animals</topic><topic>Apoptosis</topic><topic>biomarkers</topic><topic>canine</topic><topic>Cicatrix</topic><topic>Cicatrix - prevention & control</topic><topic>cornea</topic><topic>Corneal Diseases</topic><topic>Corneal Diseases - drug therapy</topic><topic>Corneal Keratocytes</topic><topic>Corneal Keratocytes - drug effects</topic><topic>culture media</topic><topic>Dog Diseases</topic><topic>Dog Diseases - drug therapy</topic><topic>Dogs</topic><topic>Dose-Response Relationship, Drug</topic><topic>drug effects</topic><topic>drug therapy</topic><topic>fetal bovine serum</topic><topic>fibroblasts</topic><topic>Fibroblasts - drug effects</topic><topic>fibrosis</topic><topic>in vitro studies</topic><topic>in vivo studies</topic><topic>metaplasia</topic><topic>microscopy</topic><topic>mitomycin</topic><topic>Mitomycin - therapeutic use</topic><topic>mitomycin C</topic><topic>muscles</topic><topic>phenotype</topic><topic>polymerase chain reaction</topic><topic>prevention & control</topic><topic>protein synthesis</topic><topic>RNA</topic><topic>Stromal Cells</topic><topic>Stromal Cells - drug effects</topic><topic>therapeutic use</topic><topic>toxicity</topic><topic>transforming growth factors</topic><topic>viability</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, Rangan</creatorcontrib><creatorcontrib>Yarnall, Benjamin W.</creatorcontrib><creatorcontrib>Giuliano, Elizabeth A.</creatorcontrib><creatorcontrib>Kanwar, Jagat R.</creatorcontrib><creatorcontrib>Buss, Dylan G.</creatorcontrib><creatorcontrib>Mohan, Rajiv R.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Veterinary ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, Rangan</au><au>Yarnall, Benjamin W.</au><au>Giuliano, Elizabeth A.</au><au>Kanwar, Jagat R.</au><au>Buss, Dylan G.</au><au>Mohan, Rajiv R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mitomycin C: a promising agent for the treatment of canine corneal scarring</atitle><jtitle>Veterinary ophthalmology</jtitle><addtitle>Vet Ophthalmol</addtitle><date>2011-09</date><risdate>2011</risdate><volume>14</volume><issue>5</issue><spage>304</spage><epage>312</epage><pages>304-312</pages><issn>1463-5216</issn><eissn>1463-5224</eissn><abstract>Objective To evaluate the safety and efficacy of mitomycin C (MMC) in prevention of canine corneal scarring.
Methods With an in vitro approach using healthy canine corneas, cultures of primary canine corneal fibroblasts or myofibroblasts were generated. Primary canine corneal fibroblasts were obtained by growing corneal buttons in minimal essential medium supplemented with 10% fetal bovine serum. Canine corneal myofibroblasts were produced by growing cultures in serum‐free medium containing transforming growth factor β1 (1 ng/mL). Trypan blue assay and phase‐contrast microscopy were used to evaluate the toxicity of three doses of MMC (0.002%, 0.02% and 0.04%). Real‐time PCR, immunoblot, and immunocytochemistry techniques were used to determine MMC efficacy to inhibit markers of canine corneal scarring.
Results A single 2‐min treatment of 0.02% or less MMC did not alter canine corneal fibroblast or keratocyte phenotype, viability, or growth. The 0.02% dose substantially reduced myofibroblast formation (up to 67%; P < 0.001), as measured by the change in RNA and protein expression of fibrosis biomarkers (α‐smooth muscle actin and F‐actin).
Conclusion This in vitro study suggests that a single 2‐min 0.02% MMC treatment to the canine corneal keratocytes is safe and may be useful in decreasing canine corneal fibrous metaplasia. In vivo studies are warranted.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21929607</pmid><doi>10.1111/j.1463-5224.2011.00877.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1463-5216 |
| ispartof | Veterinary ophthalmology, 2011-09, Vol.14 (5), p.304-312 |
| issn | 1463-5216 1463-5224 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3354612 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | actin Actins Animals Apoptosis biomarkers canine Cicatrix Cicatrix - prevention & control cornea Corneal Diseases Corneal Diseases - drug therapy Corneal Keratocytes Corneal Keratocytes - drug effects culture media Dog Diseases Dog Diseases - drug therapy Dogs Dose-Response Relationship, Drug drug effects drug therapy fetal bovine serum fibroblasts Fibroblasts - drug effects fibrosis in vitro studies in vivo studies metaplasia microscopy mitomycin Mitomycin - therapeutic use mitomycin C muscles phenotype polymerase chain reaction prevention & control protein synthesis RNA Stromal Cells Stromal Cells - drug effects therapeutic use toxicity transforming growth factors viability |
| title | Mitomycin C: a promising agent for the treatment of canine corneal scarring |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T21%3A25%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mitomycin%20C:%20a%20promising%20agent%20for%20the%20treatment%20of%20canine%20corneal%20scarring&rft.jtitle=Veterinary%20ophthalmology&rft.au=Gupta,%20Rangan&rft.date=2011-09&rft.volume=14&rft.issue=5&rft.spage=304&rft.epage=312&rft.pages=304-312&rft.issn=1463-5216&rft.eissn=1463-5224&rft_id=info:doi/10.1111/j.1463-5224.2011.00877.x&rft_dat=%3Cproquest_pubme%3E1420128491%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1420128491&rft_id=info:pmid/21929607&rfr_iscdi=true |